Published in Br J Cancer on January 26, 2010
Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med (2014) 1.08
A rare bladder cancer--small cell carcinoma: review and update. Orphanet J Rare Dis (2011) 1.08
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer (2010) 1.06
MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res (2010) 1.02
Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol (2010) 0.98
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle (2011) 0.95
Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab Invest (2015) 0.88
Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci (2014) 0.87
Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations. Rare Tumors (2015) 0.78
Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer. Mol Clin Oncol (2017) 0.75
Expression of Notch1 and Numb in small cell lung cancer. Oncotarget (2017) 0.75
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS One (2016) 0.75
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Res Notes (2015) 0.75
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
The new lung cancer staging system. Chest (2009) 6.30
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med (1992) 5.10
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol (1992) 3.27
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol (2006) 2.91
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol (2002) 2.65
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2009) 2.58
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol (2008) 2.34
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet (1973) 2.12
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol (2006) 1.88
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol (2008) 1.88
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol (2007) 1.79
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol (2006) 1.77
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer (2006) 1.77
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer (2005) 1.73
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol (2007) 1.67
Small cell lung cancer: have we made any progress over the last 25 years? Oncologist (2007) 1.62
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol (1992) 1.40
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol (2004) 1.37
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer (2007) 1.29
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol (2010) 1.29
Lung cancer screening: the way forward. Br J Cancer (2008) 1.28
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol (2009) 1.27
Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) (1998) 1.24
Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol (2007) 1.21
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol (1994) 1.19
Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev (2005) 1.17
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol (2005) 1.15
Staging and clinical prognostic factors for small-cell lung cancer. Cancer J (2001) 1.12
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer (1998) 1.11
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol (2001) 1.09
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol (2005) 1.08
Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology (1992) 1.05
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol (2003) 1.01
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol (2011) 0.99
Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol (2009) 0.99
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol (1998) 0.98
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer (2010) 0.98
Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev (2008) 0.96
Recent advances in management of small-cell lung cancer. Cancer Treat Rev (2004) 0.95
Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials (2008) 0.94
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax (2008) 0.94
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res (2002) 0.92
A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist (2004) 0.91
Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer (1993) 0.90
Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist (2004) 0.90
Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol (2001) 0.90
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol (2007) 0.89
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer (2007) 0.89
Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer (1999) 0.88
A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer. Chest (1997) 0.87
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer (2008) 0.86
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer (2007) 0.85
Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol (2008) 0.85
Chemotherapy strategies in the treatment of small cell lung cancer. Anticancer Drugs (2005) 0.84
Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist (2004) 0.83
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer (1993) 0.83
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer (2003) 0.83
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1995) 0.81
Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology (1996) 0.81
Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer (2006) 0.81
First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol (1988) 0.81
Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev (2000) 0.79
Topotecan in relapsed small-cell lung cancer: can good things come in small packages? Clin Lung Cancer (2003) 0.79
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol (2005) 0.78
High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group. Br J Cancer (1989) 0.76
Topotecan for the treatment of small-cell lung cancer. Expert Rev Anticancer Ther (2007) 0.76
Radiotherapy in extensive-disease small cell lung cancer. A survey of current UK practice. Clin Oncol (R Coll Radiol) (2008) 0.76
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.46
A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital. Br Dent J (2013) 1.44
Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut (2005) 1.29
Contribution of the MHC region to the familial risk of coeliac disease. J Med Genet (1999) 1.20
The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer (2003) 1.10
Oral surgery: ARONJ masterclass. Br Dent J (2014) 1.06
Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer (2006) 0.94
Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer (2007) 0.94
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax (2004) 0.92
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol (2004) 0.91
Before you reach for the bleach... Br Dent J (2011) 0.90
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia (1999) 0.89
Genome screening of coeliac disease. J Med Genet (2002) 0.87
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst (2005) 0.86
Terminal ileitis with sealed perforation--a rare complication of intestinal endometriosis: case report and short review of the literature. Arch Gynecol Obstet (2003) 0.84
Dietary practices in pyridoxine non-responsive homocystinuria: a European survey. Mol Genet Metab (2013) 0.84
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. Eur J Cancer (2011) 0.83
[Preliminary study on mycotic anemophilous lora of Belo Horizonte, Minas Gerais. I. Frequencey of the fungi genera of allergic interest]. Rev Inst Med Trop Sao Paulo (1968) 0.82
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer (2002) 0.82
Dietary management of urea cycle disorders: European practice. Mol Genet Metab (2013) 0.82
Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer (2006) 0.81
Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication. Eur J Cancer (2011) 0.81
A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) (2002) 0.81
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol (2014) 0.81
Field evaluation of the repellents deet, CIC-4, and AI3-37220 against Anopheles in Lae, Papua New Guinea. J Am Mosq Control Assoc (1999) 0.81
The effectiveness of light, 1-octen-3-ol, and carbon dioxide as attractants for anopheline mosquitoes in Madang Province, Papua New Guinea. J Am Mosq Control Assoc (2004) 0.80
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer (2010) 0.80
Field evaluation of repellents containing deet and AI3-37220 against Anopheles koliensis in Papua New Guinea. J Am Mosq Control Assoc (2001) 0.79
Occupational contact dermatitis from vitamin K3 sodium bisulphite. Contact Dermatitis (1988) 0.79
Modulation of MPP+ uptake by tea and some of its components in Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.79
Effects of extracts of selected medicinal plants upon hepatic oxidative stress. J Med Food (2010) 0.78
Brain MRI findings as an important diagnostic clue in glutaric aciduria type 1. Neuroradiol J (2013) 0.78
A parallel increase in placental oxidative stress and antioxidant defenses occurs in pre-gestational type 1 but not gestational diabetes. Placenta (2013) 0.78
Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer. Clin Oncol (R Coll Radiol) (2008) 0.78
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br J Cancer (2002) 0.78
Is capecitabine efficacious in triple negative metastatic breast cancer? Oncology (2011) 0.78
Relative power of linkage and transmission disequilibrium test strategies to detect non-HLA linked coeliac disease susceptibility genes. Gut (1999) 0.78
Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK. Eur J Cancer Care (Engl) (2012) 0.77
Allergic contact dermatitis in children. A multicenter study of the Portuguese Contact Dermatitis Group (GPEDC). Contact Dermatitis (1992) 0.76
Contemporary tools for the analysis of episodic growth hormone secretion and clearance in vivo. Acta Paediatr Scand Suppl (1988) 0.76
Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control. Lung Cancer (2005) 0.76
Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer (2002) 0.76
The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer. Lung Cancer (2010) 0.75
Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer (2010) 0.75
An unusual cause of chest pain. Postgrad Med J (1997) 0.75
Ex utero intrapartum procedure for delivery of a fetus with a large cervical mass. Eur J Anaesthesiol (2005) 0.75
[Prevention of the adverse effects of immobility]. Servir (1995) 0.75
Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung Cancer (2011) 0.75
[Periarteritis nodosa with initial ocular involvement]. J Fr Ophtalmol (1995) 0.75
[Preliminary study on airborne fungi in the city of Belo Horizonte, Minas Gerais. II. Skin sensitivity to the 4 most common genera in patients with respiratory allergy]. Rev Inst Med Trop Sao Paulo (1969) 0.75
[Enalapril in the treatment of mild and moderate arterial hypertension. Amplification of the Brazilian multicenter study]. AMB Rev Assoc Med Bras (1989) 0.75
Pulsatile release and circadian rhythms of thyrotropin and prolactin in children with growth hormone deficiency. Pediatr Res (1996) 0.75